DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1948)

Coronary Heart Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Stable Angina (US)

Coronary Heart Disease | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Stable Angina (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

May 2019

Stable angina is the most common clinically evident manifestation of coronary heart disease (CHD); it is present in almost half of all prevalent CHD cases. The aim of chronic medical therapy is to minimize symptoms and prevent CHD progression. Acute attacks of stable angina are typically managed with nitrates, while first-line chronic antianginal treatment typically consists of beta blockers, long-acting nitrates, or calcium channel blockers. The branded antianginal drug Ranexa (ranolazine) is used in later lines when initial treatment is unsuccessful. Meanwhile, antiplatelet agents, statins, and ACE inhibitors are typically used to prevent CV events. Using a longitudinal claims data analysis, we demonstrate how stable angina is being treated in the United States and provide insights into what is driving current prescribing practices for newly diagnosed and recently treated patients.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed stable angina patients?
  • What are the quarterly trends in prescribing among recently treated and newly diagnosed stable angina patients?
  • How has stable angina been integrated into the treatment algorithm and what is its source of business?
  • What percentage of stable angina patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of stable angina patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated stable angina patients?

Geography: United States

Real World Data: Longitudinal patient-level claims data analysis

Key Drugs Covered: Beta blockers, calcium channel blockers, nitrates, antiplatelet agents, statins, ACE inhibitors, Ranexa (ranolazine).

Key Analysis Provided: Brand/therapy usage across longitudinal patient sample. Newly diagnosed patient analysis. Treatment initiation and progression. Line of therapy analysis. Combination therapy analysis. Source of business for recently treated patients. Persistency and compliance analysis. Product-level patient flowcharts.

PRODUCT DESCRIPTION: Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Stable Angina (US)
    • Treatment Algorithms Stable Angina US May 2019

Already a Client? Log in to access this report.

  • Pub Date: May 2019
  • Author(s): Kahkashan Resham, Ph.D
  • Kahkashan Resham is a senior research associate in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. Her current work is focused on writing treatment algorithm reports, key opinion leader identification, clinical trial pipeline pulls, as well as secondary research across multiple cardiovascular and metabolic indications. Prior to joining DRG, Resham obtained her doctorate in Pharmacology from National Institute of Pharmaceutical Education and Research (NIPER), Nagar, India. She completed her M. Pharm. from the NIPER Hyderabad and was awarded a gold medal for securing 1st rank in the Institute. She holds a bachelor’s degree in Pharmacy from Birla Institute of Technology, Ranchi, India. Resham has also published several peer-reviewed research articles in the area of drug metabolism, diabetes and chemotherapy-induced peripheral neuropathic pain.

Purchase Report

Recent reports:
You may also be interested in: